Transgene : TG4001 n’atteint pas son critère primaire en phase 2
>Echec de TG4001 - Nous apprenons ce matin que les premiers résultats de l’essai de phase 2 évaluant TG4001 en combinaison avec Bavencio de Merck KgaA n’a pas atteint son critère primaire chez des patients atteints de tumeurs du col de l’utérus et anogénitales HP16-positives (induit par le papillomavirus) récurrentes ou métastatiques. Nous n’avons, à ce stade, aucun détail sur ces résultats ni sur leur teneur. Nous pouvons souligner deux aspects : il semblerait q...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.